Vimarsana
Biggest News Aggregation in the World

Page 34 - Mobile Opera News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mobile Opera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mobile Opera Today - Breaking & Trending Today

Abbott restarts production of infant formulas at Michigan plant - Vimarsana News

Abbott restarts production of infant formulas at Michigan plant

Abbott Nutrition restarted production of infant formulas at a Michigan plant that was shut down for months after the company initiated a recall of its powder formulas, beginning the country’s ongoing formula shortage.

Source: healio.com
Benefits of tubeless closed-loop insulin delivery system sustained at 1 year in young kids - Vimarsana News

Benefits of tubeless closed-loop insulin delivery system sustained at 1 year in young kids

NEW ORLEANS — New data show sustained glycemic improvements and safety at 1 year in very young children with type 1 diabetes who used a tubeless hybrid closed-loop insulin delivery system, researchers reported.Improved glycemic outcomes and safety in the initial 3-month pivotal study of the Omnipod 5 system (Insulet) in very young children persisted for an additional 9 months in an ongoing

Source: healio.com
Food allergy associated with lower SARS-CoV-2 infection risk - Vimarsana News

Food allergy associated with lower SARS-CoV-2 infection risk

People with food allergies showed lower risk for SARS-CoV-2 infection, whereas those with obesity had a higher risk, according to a study published in The Journal of Allergy and Clinical Immunology. Additionally, results of the perspective surveillance study showed asthma did not positively or negatively impact risk for SARS-CoV-2 infection.

Source: healio.com
Infliximab may lead to higher infection rate, no improvement in transplant outcomes - Vimarsana News

Infliximab may lead to higher infection rate, no improvement in transplant outcomes

The use of infliximab in patients with a deceased donor kidney transplant led to increased infections and did not improve allograft survival, according to data presented at the American Transplant Congress. “The intervention had no effect on allograft function or acute rejection,” Peter S. Heeger, MD, a professor of medicine and immunology at the Icahn School of Medicine at Mount

Source: healio.com
Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset - Vimarsana News

Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer, phase 2 study results showed.Longer follow-up is needed to examine the duration of treatment response in this patient population, according to researchers of the study, reported at ASCO

Source: healio.com